PROCEPT BioRobotics to Highlight Aquablation Expansion at Upcoming Piper Sandler Event
Company Presentation: PROCEPT BioRobotics Corp. will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, focusing on its Aquablation therapy and HYDROS Robotic System.
Financial Performance: For Q3 2025, PROCEPT reported a net loss of $21.4 million, despite a 43% increase in revenue to $83.3 million, driven by strong demand for its products.
Revenue Growth: U.S. revenue rose to $73.9 million, a 42% increase from the previous year, while international revenue grew by 53% to $9.4 million, indicating strong market adoption.
Future Outlook: The company anticipates full-year revenue of approximately $325.5 million for fiscal 2025, up from $224.5 million in 2024, supported by a solid cash position of $297.3 million.
Get Free Real-Time Notifications for Any Stock
Analyst Views on PRCT
About PRCT
About the author
PRCT Options Analysis: Put Contract Offers 4.4% YieldBoost Potential
- Put Contract Yield: The $25.00 put contract for PRCT has a current bid of $1.10, and if an investor sells to open this contract, they commit to buying shares at $25.00, resulting in a cost basis of $23.90, which represents a 17% discount compared to the current price of $30.29, making it attractive for potential buyers.
- Expiration Risk Analysis: Current data suggests a 79% chance that the put contract will expire worthless, which would yield a 4.40% return on the cash commitment, or an annualized yield of 27.71%, referred to as YieldBoost, highlighting the contract's appeal.
- Call Contract Returns: The $32.50 call contract for PRCT has a current bid of $2.00, and if an investor buys shares at $30.29 and sells this contract, they could achieve a total return of 13.90% if the stock is called away at expiration, showcasing the potential profitability of this strategy.
- Volatility Comparison: The implied volatility for the put contract is 74%, while for the call contract it is 81%, compared to an actual trailing twelve-month volatility of 54%, indicating a high market expectation for future price fluctuations in PRCT stock, necessitating careful risk assessment by investors.
ETFs on the Move This Monday: REMX, IHI
ETF Performance: The iShares U.S. Medical Devices ETF is underperforming, down approximately 1.7% in Monday afternoon trading.
Weakest Components: Notable declines among ETF components include Axogen, which fell by about 4.9%, and Procept Biorobotics, down by about 4.2%.
Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
